Bristol-Myers Squibb (BMY) Stock
Key stats
- Market cap
- $128.59B
- Price / Earnings ratio
- 13.9x
- EPS (TTM)
- $4.53
- Volume
- Loading
- 52-week high
- $68.64
- 52-week low
- $45.27
- Dividend yield
- 4.01%
- Dividend amount (latest)
- $0.63
- EPS vs analyst estimate
- +7.9%Q3 FY25 · $1.63 vs $1.51
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with BMY
Recent news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
BMY

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
BMY

BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
BMY

BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
BMY
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.11
- MACD 12/26/9
- 0.39
- EMA 9 of MACD
- 0.20
- MACD histogram
- 0.18
- SMA 50
- $62.10
- Price above SMA 50
- EMA 50
- $61.98
- Price above EMA 50
- SMA 200
- $60.26
- Price above SMA 200
- EMA 200
- $59.47
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.51 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets
BMY

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?
BMY

BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
BMY

BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
BMY

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
BMY

Bristol Myers Squibb Q3 Earnings Call Highlights
Bristol Myers Squibb Q3 Earnings Call Highlights
BMY

Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
Bristol Myers' Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction
BMY

BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook
BMY

Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 Earnings
Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q3 Earnings
BMY

Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat Estimates
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat Estimates
BMY
News tone: automated (AI) classification of the article's content, not a price prediction.
About Bristol-Myers Squibb
We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We work every day to transform patients’ lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Christopher S. Boerner Ph.D. | CEO & Chairman | 1971 |
| Mr. David V. Elkins | Executive VP & CFO | 1968 |
| Mr. Greg Meyers | Executive VP and Chief Digital & Technology Officer | 1973 |
| Mr. Adam Lenkowsky | Executive VP & Chief Commercialization Officer | 1972 |
| Mr. Cristian Massacesi M.D. | Executive VP, Chief Medical Officer & Head of Development | 1969 |
| Ms. Karin Shanahan | Executive VP, Chief Supply Chain & Operations Officer | 1965 |
| Mr. Charles E. Triano | SVP & Head of Investor Relations | — |
| Ms. Cari Gallman | Executive VP, General Counsel & Chief Policy Officer | 1980 |
| Ms. Ahn Amanda Poole | Executive VP & Chief People Officer | 1975 |
| Dr. Joseph J. Eiden Jr. | Head of Medical Affairs | 1949 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 54.11
- MACD 12/26/9
- 0.39
- EMA 9 of MACD
- 0.20
- MACD histogram
- 0.18
- SMA 50
- $62.10
- Price above SMA 50
- EMA 50
- $61.98
- Price above EMA 50
- SMA 200
- $60.26
- Price above SMA 200
- EMA 200
- $59.47
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $40.00
- Average
- $59.17
- High
- $78.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.0 | +13.5 | ||||||||||
| 2022 | +4.9 | +5.3 | +6.4 | +2.0 | +0.5 | +2.7 | -4.0 | -8.4 | +2.9 | +9.8 | +3.3 | -11.0 |
| 2023 | +0.5 | -3.2 | -0.1 | -4.2 | -5.8 | -1.1 | -3.5 | +0.2 | -6.4 | -10.9 | -3.7 | +2.4 |
| 2024 | -7.4 | +4.3 | +6.6 | -17.1 | -7.1 | -0.6 | +15.2 | +3.7 | +2.4 | +5.4 | +9.0 | -5.6 |
| 2025 | +3.8 | -0.6 | +1.9 | -15.7 | -2.7 | -5.1 | -8.8 | +6.7 | -4.9 | -2.9 | +6.9 | +9.7 |
| 2026 | +3.0 | +11.6 | -2.7 | -1.8 | -1.8 | +4.9 | +15.7 | +2.0 | -6.8 | +1.7 | -0.3 |
Corporate actions
Upcoming
No upcoming corporate actions for BMY



